NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

Integra LifeSciences Holdings Corporation (IART) Stock Analysis

Integra LifeSciences Holdings Corporation (IART) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

IART

$16.72

+$0.28 (+1.70%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IART with… →

IART Key Statistics

As of Sep 4, 2026
Trading
Open
$16.32
Previous Close
$16.44
Day's Range
16.25–16.78
52-Week Range
8.70–20.49
Volume
674.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.21
Valuation
Market Cap
$1.30B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
6.41
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.67
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.79
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.09
Financials (FY)
Revenue (FY)
$1.64B+1.53%
Net Income (FY)
−$516.47M
Profit marginThe share of revenue left as profit after all costs and taxes.
−0.44%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
77.77M
1-Year Return
+6.84%
Dividend and dates
Earnings Date
October 29, 2026estimated
Avg Volume
860.23K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IART Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+34.62%
2025−45.24%
2024−47.92%
2023−22.33%
2022−16.30%
2021+3.19%
2020+11.39%
2019+29.22%
2018−5.77%
2017+11.57%
2016 (partial year)+2.02%

As of September 4, 2026.

IART Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.64B−$516.47M−31.6%
2024$1.61B−$6.94M−0.4%
2023$1.54B$67.74M4.4%
2022$1.56B$180.55M11.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.64B$831.62M$18.00M−$516.47M−31.6%
2024$1.61B$882.06M$28.41M−$6.94M−0.4%
2023$1.54B$884.74M$111.53M$67.74M4.4%
2022$1.56B$970.31M$238.92M$180.55M11.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IART Valuation vs Medical Devices Median

Median of 151 stocks
MetricIARTMedical Devices medianvs median
P/S ratio0.792.980.3x the median
Profit margin−0.44%−1.69%1.3 pts above

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Integra LifeSciences Holdings Corporation (IART) carries a market capitalisation of $1.30B. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 4,427.

The most recent close on file for IART is $16.72, dated September 4, 2026. That is +$0.28 (+1.70%) against the previous close. Over the past 52 weeks the price has ranged from $8.70 to $20.49. The latest close sits 92.18% above that 52-week low.

Financial Health

In fiscal 2025, Integra LifeSciences Holdings Corporation reported revenue of $1.64B. Against the prior fiscal year total of $1.61B, that is a change of +1.53%. The same year closed with a net loss of $516.47M. Profit margin runs at −0.44%. That is 1.3 percentage points above the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −0.09.

Across the 4 fiscal years on file, revenue moves from $1.56B in 2022 to $1.64B in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 6.41. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.67. The price-to-sales ratio is 0.79. On price-to-sales that is 0.3 times the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

The reported beta is 1.21. Annualized volatility over the trailing 10 years is 40.56%. Over the trailing twelve months the price has returned +6.84%. Across 10 years the annualized return works out at −9.14%.

Growth & Income

The record shows no dividend for IART.

The strongest complete calendar year on file is 2019 at +29.22%; the weakest is 2024 at −47.92%. Of the 9 complete calendar years on file, 4 finished higher. So far in 2026 the price is +34.62%.

Peer Comparison

Integra LifeSciences Holdings Corporation (IART) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Integra LifeSciences Holdings Corporation IART $1.30B —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Integra LifeSciences Holdings Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Visit website →